臨床實驗室之質譜分析 是由出版商Trimark Publications在2011年11月所出版的。
這份英文市場調查報告書包含165 Pages 價格從美金3400起跳。
本報告為，詳細分析質譜藥物測試市場，並匯整市場規模、成長展望、技術平台、臨床應用、新設備、產業趨勢、歐美及日本為中心之地區別趨勢等，以下列摘要形式闡述。
第1章 概要
第2章 臨床實驗室之質譜藥物測試分析簡介
- 臨床實驗室質譜分析測試及儀器
- 質譜分析設備概要
- 質譜分析之臨床應用
- 治療藥物監測
- 代謝性疾病
- 內分泌
- 臨床毒性
- 蛋白質組學
- 生物標誌物
- 質譜分析及臨床診斷之機會
- 質譜分析測試市場之發展
- 質譜分析技術之進步
第3章 質譜分析測試市場
第4章 臨床實驗室之質譜分析診斷測試
- 使用質譜分析之臨床實驗室分子測試
- 主要檢測
- 質譜分析臨床診斷之挑戰
- 質譜分析擴大新的應用領域
- 微生物學
- 代謝
- 癌症治療
- 免疫抑製劑
- 疼痛管理藥物
- 質譜分析市場之範式轉換
- 代謝蛋白質組學自動化工作站生物標誌物
- 多重化
- 使用質譜分析於生物標誌之藥物發現
- 技術進步／創新
第5章 臨床實驗室之質譜分析商業環境
- 技術及市場趨勢
- M&A活動
- 合作
- 競合分析
- 質譜分析臨床產品之成功
- 智慧財產權
- 機會及策略性建議
- 質譜分析臨床產品之商業模式
第6章 產品開發／競合環境
第7章 使用臨床實驗室測試領域質譜分析平台時之商業決策、策略展望、建議
第8章 企業簡介
- AB SCIEX
- Agilent Technologies
- Applied Biosystems/Sciex
- bioMerieux
- Bruker
- Danaher Corporation
- Hiden Analytical
- JEOL
- Konica Minolta
- MDS Analytical Technologies
- PerkinElmer
- 島津製作所
- Spectro
- Thermo Fisher Scientific
- Varian
- Waters Corporation
圖表
Abstract
Mass spectroscopy is a clinical laboratory analysis technique used in
determining the basic composition and structure of a sample or molecule. The
process involves bending a charged beam of vaporized material using an
electric and/or magnetic field and then plotting a spectrum of how the
sample's ions are deflected. Mass spectroscopy assays based on well-documented
techniques such as time-of-flight, liquid chromatography/tandem, liquid
chromatography, gas chromatography-quadrupole and others have gained wide
acceptance in the clinical laboratory due to their accuracy, speed and
sensitivity compared to traditional analytical drug detection techniques. This
TriMark Publications report provides a detailed analysis of the mass
spectroscopy drug testing market, including size, growth, technology
platforms, clinical applications, new instrumentation, industry trends and the
internal structure of the sector. The mass spectroscopy market remains the
fastest-growing segment of the diagnostics analytical instruments market.
Highly-attractive clinical growth areas covered in this study include: disease
markers; molecular diagnostics; infectious disease; toxicology; inborn errors
in metabolism; metabolomics; proteins and peptides; small molecule analytes
(vitamins, steroids, thyroid, etc.); tobacco exposure; chemical warfare
agents; tissue analysis by MALDI; clinical chemistry/toxicology;
microbiology/virology; proteomic, metabolomic and tissue histology
laboratories; high-end MS; and food testing. Also provided in this review is a
thorough analysis of the companies known to be marketing, manufacturing or
developing mass spectroscopy products in the U.S. and worldwide, as well as
detailed tables, charts and figures with past and projected data analyzed by
geographic region with a focus on the U.S., Europe and Japan, the
world's three largest mass spectroscopy markets.
METHODOLOGY
The senior author of this report holds a Ph.D. in biochemistry from the
University of Minnesota, with many decades of experience in science writing
and as a medical industry analyst. He has over 40 years of experience as a
director in laboratory testing and instrument and reagent development
technology, as well as extensive experience in senior level positions in
biotech and medical service companies. The contributing analyst has a Ph.D. in
chemistry from the University of Illinois, with more than 30 years of
experience as a clinical laboratory director, as well as editing and writing
articles in science and technology. He is currently laboratory director of a
large urban hospital whose lab specializes in mass spectroscopy and drug
analysis. Company-specific information is obtained mainly from industry trade
publications, academic journals, news and research articles, press releases
and corporate websites, as well as annual reports for publicly-held firms.
Additional sources of information include non-governmental organizations
(NGOs) such as the World Health Organization (WHO) and governmental entities
such as the U.S. Department of Health and Human Services (HHS), the National
Institutes of Health (NIH), the Food and Drug Administration (FDA) and the
Centers for Disease Control and Prevention (CDC). Where possible and
practicable, the most recent data available have been used.
Some of the statistical information was taken from Biotechnology Associates'
database and from TriMark's private data stores. The information in this study
was obtained from sources that we believe to be reliable, but we do not
guarantee the accuracy, adequacy or completeness of any information or
omission or for the results obtained by the use of such information. Key
information from the business literature was used as a basis to conduct
dialogue with and obtain expert opinion from market professionals regarding
commercial potential and market sizes. Senior managers from major company
players were interviewed for part of the information in this report. Primary
Sources
Table of Contents
1. Overview
- 1.1. Statement of Report
- 1.2. About This Report
- 1.3. Scope of the Report
- 1.4. Objectives
- 1.5. Methodology
- 1.6. Executive Summary
2. Introduction to Mass Spectroscopy for Clinical Laboratory Testing
- 2.1. Mass Spectroscopy Testing and Opportunities in the Clinical
Laboratory Sector
- 2.2. Overview of Laboratory Mass Spectroscopy Instrumentation
- 2.2.1. Clinical Applications of Mass Spectrometry
- 2.2.1.1. Therapeutic Drug Monitoring
- 2.2.1.2. Metabolic Diseases
- 2.2.1.3. Endocrinology
- 2.2.1.4. Clinical Toxicology
- 2.2.1.5. Proteomics
- 2.2.1.6. Biomarkers
- 2.3. Opportunities in Mass Spectroscopy and Clinical Diagnostics
- 2.4. Development of Mass Spectroscopy Testing Markets
- 2.5. Mass Spectrometry
- 2.5.1. Overview of Mass Spectrometry
- 2.5.2. Sample Introduction Techniques
- 2.5.3. Ionization Source
- 2.5.3.1. Electrospray Ionization
- 2.5.3.2. Electron Ionization
- 2.5.3.3. Matrix-Assisted Laser Desorption/Ionization (MALDI)
- 2.5.4. Mass Analyzers
- 2.5.4.1. Quadrupoles
- 2.5.4.2. Quadrupole Ion Trap
- 2.5.4.3. Linear Ion Trap
- 2.5.4.4. Quadrupole Time-of-Flight Tandem MS (TOF)
- 2.5.4.5. MALDI with Time-of-Flight Analysis (MALDI-TOF)
- 2.5.4.6. Quadrupole Time-of-Flight MS
- 2.5.4.7. Fourier Transform Mass Spectrometry (FTMS)
- 2.5.5. Ion Detectors
- 2.6. Advances in Mass Spectroscopy Technologies
- 2.6.1. Market Drivers and Restraints
- 2.6.1.1. Market Drivers
- 2.6.1.2. Market Restraints
- 2.6.2. Market and Technology Trends
- 2.6.2.1. Market Trends
- 2.6.2 2. Technology Trends
- 2.6.3. Strategic Recommendations
3. Mass Spectroscopy Diagnostics Testing Market
- 3.1. Market Overview
- 3.1.1. Overall Mass Spectroscopy Clinical Laboratory Market Analysis
- 3.2. Mass Spectroscopy Diagnostics Market
- 3.3. Mass Spectroscopy Clinical Testing Platforms
- 3.3.1. Gas Chromatography/Mass Spectrometry (GC/MS)
- 3.3.1.1. Background
- 3.3.1.2. Instruments
- 3.3.1.3. Method Comparisons
- 3.3.1.4. Market Drivers and Restraints
- 3.3.1.4.1. Market Drivers
- 3.3.1.4.2. Market Restraints
- 3.3.1.5. Market and Technology Trends
- 3.3.1.5.1. Market Trends
- 3.3.1.5.2. Technology Trends
- 3.3.1.5.3. Strategic Recommendations
- 3.3.2. Ion Trap and Quadrupole Mass Spectrometers
- 3.3.2.1. Background
- 3.3.2.1.1. Instruments
- 3.3.2.1.2. Method Comparisons
- 3.3.2.1.3. Market Challenges and Strategic Recommendations
- 3.3.2.1.3.1. Market Drivers and Restraints
- 3.3.2.1.3.1.1. Market Drivers
- 3.3.2.1.3.1.2. Market Restraints
- 3.3.2.1.4. Market and Technology Trends
- 3.3.2.1.4.1. Market Trends
- 3.3.2.1.4.2. Technology Trends
- 3.3.2.1.5. Strategic Recommendations
- 3.3.3. Liquid Chromatography/Mass Spectrometry
- 3.3.3.1. Background
- 3.3.3.2. Instruments
- 3.3.3.3. Method Comparisons
- 3.3.3.4. Market Size
- 3.3.3.4.1. Liquid Chromatography/Mass Spectroscopy (LC/MS) Market
Size
- 3.3.3.4.1.1. Market Share
- 3.3.3.4.2. Market Challenges and Strategic Recommendations
- 3.3.3.4.2.1. Market Drivers and Restraints
- 3.3.3.4.2.1.1. Market Drivers
- 3.3.3.4.2.1.2. Market Restraints
- 3.3.3.4.3. Market and Technology Trends
- 3.3.3.4.3.1. Market Trends
- 3.3.3.4.3.2. Technology Trends
- 3.3.3.4.4. Strategic Recommendations
- 3.3.4. Ion Mobility and High Definition Mass Spectrometry
- 3.3.5. Liquid Chromatography Tandem Mass Spectrometry
- 3.3.6. Time-of-Flight Mass Spectrometry
- 3.3.7. Orbitrap
- 3.3.7.1. Background
- 3.3.7.2. Instruments
- 3.3.7.3. Method Comparisons
- 3.3.7.4. Market and Technology Trends
- 3.3.7.4.1. Market Trends
- 3.3.7.4.2. Technology Trends
- 3.3.7.4.3. Strategic Recommendations
- 3.3.8. Matrix-Assisted Laser Desorption/Ionization (MALDI)
Time-of-Flight Mass Spectrometry
- 3.3.9. Inductively coupled Plasma Mass Spectrometry (ICP)
- 3.3.9.1. Background
- 3.3.9.2. Instruments
- 3.3.9.3. Method Comparisons
- 3.3.10. FTMS
4. Mass Spectrometry Diagnostic Testing in the Clinical Laboratory
- 4.1. Clinical Laboratory Molecular Tests Using Mass Spectroscopy
- 4.2. Top Mass Spectroscopy Assays
- 4.2.1. Drugs of Abuse
- 4.2.2. Therapeutic Drugs
- 4.2.3. Hormone Analysis
- 4.2.3.1. Vitamin D
- 4.2.3.2. Testosterone and Estradiol
- 4.2.3.3. Other Hormones
- 4.2.4. Newborn Screening
- 4.3. Challenges in Mass Spectrometry Clinical Diagnostic Technologies
- 4.3.1. Market Drivers and Restraints
- 4.3.1.1. Market Drivers
- 4.3.1.2. Market Restraints
- 4.3.2. Market and Technology Trends
- 4.3.2.1. Market Trends
- 4.3.2.2. Technology Trends
- 4.3.3. Strategic Recommendations
- 4.3.4. Cost of Mass Spectroscopy Testing
- 4.3.5. Priorities for Vendors
- 4.3.6. Mass Spectrometers Market Continues to Grow
- 4.4. Mass Spectroscopy Develops Novel Applications
- 4.4.1. Microbiology
- 4.4.2. Metabolomics
- 4.4.3. Cancer Therapy
- 4.4.4. Immunosuppressant Drugs
- 4.4.5. Pain Management Drugs
- 4.5. Paradigm Shift within the Mass Spectrometry Market
- 4.6. Metabolomics
- 4.7. Proteomics
- 4.8. Automated Workstations
- 4.9. Biomarkers
- 4.10. Multiplexing
- 4.11. Use of Mass Spectrometry in Biomarker Discovery
- 4.11.1. Multiple Reaction Monitoring Assays (MRMs)
- 4.11.2. Gel-based Approaches
- 4.11.3. Non-Gel-based Approaches
- 4.11.4. SELDI-TOF MS
- 4.11.5. SELDI and Prognosis
- 4.11.6. SELDI and Treatment Monitoring
- 4.11.7. Limitations of Mass Spectroscopy
- 4.12. Technological Breakthroughs/Innovations
- 4.12.1. Hybrids
- 4.12.2. Integrated and Hybrid-based MS systems
- 4.12.3. LTQ-Velos
- 4.12.4. Applied Biosystems Integrates Two MS technologies
- 4.12.5. Q-TOF-MS Leads
- 4.12.6 Agilent
- 4.12.6 Agilent?s Chip LC/MS Systems
- 4.12.7 New Virus Detection System Based on Mass Spectrometry
- 4.12.8 Orbitrap MS System
- 4.12.9 Qual-Quan Mass Spectroscopy
- 4.12.10 SISCAPA
- 4.12.11 SRM/MRM
- 4.12.12 AB Sciex?s iMethod and Cliquid Software
- 4.12.13 Microsaic Mini Mass Specs
5. Business Landscape for Mass Spectroscopy for Clinical Labs
- 5.1. Technology and Market Trends
- 5.1.1. Market Trends
- 5.1.2. Technology Trends
- 5.2. M&A Activity
- 5.3. Partnerships
- 5.4. Competitive Analysis
- 5.4.1. Primary Competitors
- 5.4.2. Industry Challenges and Strategic Recommendations
- 5.4.3. Commercialization of Mass Spectroscopy Products
- 5.5. The Success Achieved by the Mass Spectroscopy Clinical Products
- 5.6. Intellectual Property Rights
- 5.6.1. New Patents
- 5.6.2. Current Patent Disputes
- 5.7. Opportunities and Strategic Recommendations
- 5.7.1. Key Technical Opportunities with Significant Market Appeal in the
Mass Spectroscopy Space in the Next Five Years
- 5.7.2. Developments for Mass Spectroscopy Instrumentation Products
- 5.7.3. Market Penetration Strategies for Clinical Laboratory Testing
- 5.8. Business Models in Mass Spectroscopy Clinical Products
- 5.8.1. Scope of This Section
- 5.8.2. Business Models for Clinical Mass Spectroscopy Markets
- 5.8.2.1. SWOT Comparison of Business Models for Mass Spectrometry
Diagnostic Testing
- 5.8.3. Sales and Marketing Strategies for Clinical Laboratory Tests
6. Product Developments/Competitive Landscape
- 6.1. Manufacturers Decisions in the Global Analytical Instrument Industry
- 6.2. Instrument Introductions
7. Business Decisions, Strategic Outlook and Recommendations Using Mass Spectroscopy Technology Platforms in the Clinical Laboratory Testing Space
- 7.1. What are the Key Opportunities for Mass Spectroscopy in Clinical
Laboratory Testing Development and Commercialization?
- 7.2. What are the Current Obstacles for Mass Spectroscopy in Clinical
Laboratory Testing Implementation?
- 7.3. How Do Business Strategies, Such as those Relating to Acquisition,
Drive Mass Spectroscopy Strategies?
- 7.4. How Might Novel Clinical Laboratory MS Test Development Lead to
Acquisition or Partnering Strategies and their Implications for Deal Making?
- 7.5. How can Mass Spectroscopy Tests Increase Value in an Associated Drug
Marketing Plan?
- 7.6. Which Types of Clinical Laboratory Testing Should be Developed by
Mass Spectroscopy Companies?
- 7.7. How can Regulatory Oversight Drive Approval and Adoption of New
Technologies?
- 7.8. What are the Noteworthy Deals?
- 7.9. Who are the Acquirers?
- 7.10. Who are the Target Companies?
- 7.11. How will Platform Technology Companies Enter the Space?
- 7.12. Will Pharma Integrate with Diagnostics?
- 7.13. How Do Platform Technology Companies Position Themselves for
Diagnostic and Pharma Development?
- 7.14. Evaluate How Partnering and M&As will Alter the Competitive Landscape
- 7.15. Predict How FDA Regs will Impact New Diagnostic Tests
- 7.16. How can Big Pharma and Mass Spectroscopy Companies Co-develop
Biomarkers in a Model for Regulatory Acceptance?
- 7.17. How to Maximize Business Development through Biomarker Strategies?
- 7.18. What is the Best Type of Business Model for Developing Genetic
Biomarkers for Clinical Laboratory?
- 7.19. How Best can Mass Spectroscopy Provide the Most Benefit in Clinical
Laboratory Testing?
- 7.20. What are the Most Innovative Methods in Development of Mass
Spectroscopy Diagnostic Testing?
8. Company Profiles
- 8.1. AB SCIEX
- 8.2. Agilent Technologies
- 8.3. Applied Biosystems/Sciex
- 8.4. bioMerieux
- 8.5. Bruker
- 8.6. Danaher Corporation
- 8.7. Hiden Analytical
- 8.8. JEOL
- 8.9. Konica Minolta
- 8.10. MDS Analytical Technologies
- 8.11. PerkinElmer
- 8.12. Shimadzu Corporation
- 8.13. Spectro
- 8.14. Thermo Fisher Scientific
- 8.15. Varian
- 8.16. Waters Corporation
INDEX OF FIGURES
- Figure 2.1: Relationship of Mass Spectrometry Testing to Key Areas of
Clinical Diagnosis
- Figure 2.2: Magnetic or Electrostatic Sector in Mass Spectroscopy
- Figure 2.3: Triple Quadrupole (Tandem) Mass Spectroscopy
- Figure 2.4: Time-of-flight Mass Spectroscopy
- Figure 2.5: Diagram of a Quadrupole MS Analyzer
- Figure 2.6: Diagram of an Ion Trap MS Analyzer
- Figure 3.1: Mass Spectroscopy by Testing Type, 2010
- Figure 3.2: Key Players Market Share in Global Mass Spectroscopy Testing
Market
- Figure 3.3: Mass Spectroscopy World Market and Global Testing for Forensic
and Drug Testing, 2007-2010
- Figure 3.4: Global Revenue Forecast for Mass Spectroscopy, 2009-2016
- Figure 3.5: Global Market Revenue Share Forecast for Mass Spectroscopy
Testing Markets by Region, 2010 and 2016
- Figure 3.6: U.S. Market Revenue Forecast for Mass Spectroscopy, 2009-2016
- Figure 3.7: European Market Revenue Forecast for Mass Spectroscopy,
2009-2016
- Figure 3.8: Japanese Market Revenue Forecast for Mass Spectroscopy,
2009-2016
- Figure 3.9: Global Revenue Forecast for Mass Spectroscopy Forensic and
Drug Testing Market, 2009-2016
- Figure 3.10: Global Market Revenue Share Forecast for Mass Spectroscopy
Forensic and Drug Testing Markets by Region, 2010 and 2016
- Figure 3.11: U.S. Market Revenue Forecast for Mass Spectroscopy Forensic
and Drug Testing Market, 2009-2016
- Figure 3.12: European Market Revenue Forecast for Mass Spectroscopy
Forensic and Drug Testing Market, 2009-2015
- Figure 3.13: Japanese Market Revenue Forecast for Mass Spectroscopy
Forensic and Drug Testing Market, 2009-2016
- Figure 3.14: Mass Spectrometry Supplier Market Shares
- Figure 5.1: Market Growth of MS Clinical Laboratory Tests
- Figure 8.1: Agilent?s Well Distributed Worldwide Business
- Figure 8.2: Bruker?s Revenue Stream
- Figure 8.3: Bruker?s Geographic Distribution
- Figure 8.4: Thermo Fisher Laboratory Products Revenue Share
- Figure 8.5: Thermo Fisher Biosciences Revenue Shares
INDEX OF TABLES
- Table 2.1: Mass Spectrometry Utilization in the Clinical and Life Science
Space
- Table 2.2: Mass Spectrometry Tests for Clinical Applications
- Table 2.3: Emerging Mass Spectrometric Technologies
- Table 2.4: Advantages of Electrospray Ionization (ESI)
- Table 2.5: Disadvantages of Electrospray Ionization (ESI)
- Table 2.6: Advantages of Matrix-Assisted Laser Desorption/Ionization
(MALDI)
- Table 2.7: Disadvantages of Matrix-Assisted Laser Desorption/Ionization
(MALDI)
- Table 2.8: Mass Analyzers Event
- Table 2.9: Automated Mass Spectroscopy Platforms for Clinical Laboratory
Testing
- Table 2.10: Companies Marketing Products Using MS Technology Platforms
- Table 2.11: Mass Spectroscopy Market: Market Drivers Ranked in Order of
Impact
- Table 2.12: Mass Spectroscopy Market: Market Restraints Ranked in Order of
Impact
- Table 2.13: A Timeline of Mass Spectrometry
- Table 2.14: Attractive Growth Areas for Mass Spectroscopy Testing
- Table 3.1: Mass Spectroscopy World Market, 2007-2010
- Table 3.2: Mass Spectroscopy U.S. Market, 2007-2010
- Table 3.3: Mass Spectroscopy European Market, 2007-2010
- Table 3.4: Mass Spectroscopy Japan Market, 2007-2010
- Table 3.5: Mass Spectroscopy Global Testing Sectors for Forensic and Drug
Testing Market, 2007-2010
- Table 3.6: Mass Spectroscopy U.S. Testing Sectors for Forensic and Drug
Testing Market, 2007-2010
- Table 3.7: Mass Spectroscopy European Testing Sectors for Forensic and
Drug Testing Market, 2007-2010
- Table 3.8: Mass Spectroscopy Japanese Testing Sectors for Forensic and
Drug Testing Market, 2007-2010
- Table 3.9: Share of Mass Spectroscopy Testing for Life Science, Pharma,
and Clinical by Testing Type, 2010
- Table 3.10: Key Players and Market Share in Global Mass Spectroscopy
Testing Market
- Table 3.11: Revenue Model for Mass Spectrometry Testing
- Table 3.12: Mass Spectroscopy in the Clinical Market: Market Drivers
Ranked in Order of Impact
- Table 3.13: Mass Spectroscopy in the Clinical Market: Market Restraints
Ranked in Order of Impact
- Table 3.14: Global Revenue Forecast for Mass Spectroscopy, 2009-2016
- Table 3.15: U.S. Market Revenue Forecast for Mass Spectroscopy, 2009-2016
- Table 3.16: European Market Revenue Forecast for Mass Spectroscopy,
2009-2016
- Table 3.17: Japanese Market Revenue Forecast for Mass Spectroscopy,
2009-2016
- Table 3.18: Global Revenue Forecast for Mass Spectroscopy Forensic and
Drug Testing Market, 2009-2016
- Table 3.19: U.S. Market Revenue Forecast for Mass Spectroscopy Forensic
and Drug Testing Market, 2009-2016
- Table 3.20: European Market Revenue Forecast for Mass Spectroscopy
Forensic and Drug Testing Market, 2009-2015
- Table 3.21: Japanese Market Revenue Forecast for Mass Spectroscopy
Forensic and Drug Testing Market, 2009-2016
- Table 3.22: Business Factors Influencing Advanced Mass Spectroscopy
Testing Services
- Table 3.23: Companies Marketing Multiple Products in Mass Spectroscopy
Sector
- Table 3.24: Commercially Available GC/MS Spectrophotometers
- Table 3.25: GC/MS Market: Market Drivers Ranked in Order of Impact
- Table 3.26: GC/MS Market: Market Restraints Ranked in Order of Impact
- Table 3.27: Commercially Available Ion Trap MS
- Table 3.28: Commercially Available Liquid Chromatography/MS Systems
- Table 3.29: Commercially Available Orbitrap MS
- Table 3.30: Commercially Available MALDI MS
- Table 3.31: Commercially Available ICP MS
- Table 4.1: Immunoassays vs. Liquid Chromatography/Mass Spectrometry for
Clinical Analysis
- Table 4.2: Drugs-of-Abuse and Pain Management
- Table 4.3: Fastest-Growing Lab Tests, 2006-2009
- Table 4.4: Therapeutic Drugs
- Table 4.5: Utilization of Mass Spectrometry for Hormone Analysis
- Table 4.6: Steroids Commonly Measured Using MS Technology Platforms
- Table 4.7: Mass Spectroscopy Newborn Screening Program
- Table 4.8: Prevalence of Metabolic Disorders Analyzed by MS/MS
- Table 4.9: Principal Cost Factors in the Mass Spectroscopy Clinical
Laboratory Testing Market
- Table 4.10: Priorities for Vendors
- Table 4.11: Key Drivers of the Mass Spectroscopy Market in Life Sciences
- Table 4.12: Proteins Measured in Clinically-available MS Tests in the U.S.
- Table 4.13: Concentration of Some Abundant Proteins, New Cancer Biomarkers
Identified by SELDI-TOF, and Classical Cancer Biomarkers in Serum
- Table 4.14: Strengths and Limitations of MRM Assays
- Table 4.15: Software Methods for Mass Spectroscopy for Clinical Analysis
- Table 4.16: Software Methods for Mass Spectroscopy for Drugs of Abuse
Analysis
- Table 5.1: Technology Trends in Mass Spectroscopy for Clinical Laboratory
Testing
- Table 5.2: Clinical Testing Trends in Mass Spectroscopy for Clinical
Laboratory Testing
- Table 5.3: Business Market Trends in Mass Spectroscopy Clinical Laboratory
Testing
- Table 5.4: Expected Changes in Healthcare
- Table 5.5: Customer Feedback for Automated Mass Spectroscopy Instruments
- Table 5.6: Mass Spectroscopy Clinical Laboratory Market: Market Drivers
Ranked in Order of Impact
- Table 5.7: Mass Spectroscopy Clinical Laboratory Market: Market Restraints
Ranked in Order of Impact
- Table 5.8: Advantages of European Markets for Mass Spectroscopy Testing
- Table 5.9: Disadvantages of European Markets for Mass Spectroscopy Testing
- Table 5.10: Summary of Recent M&A Activity in the Mass Spectroscopy Sector
- Table 5.11: High Value Opportunities in Collaborative and Strategic
Partnerships Using MS
- Table 5.12: Principal Competitive Factors in the Mass Spectroscopy
Clinical Laboratory Testing Market
- Table 5.13: Mass Spectroscopy Clinical Laboratory Testing Market:
Strategic Recommendations on Mass spectroscopy Sector Business Functions
- Table 5.14: Mass Spectroscopy Clinical Laboratory Market: Impact of Top
Industry Challenges (U.S.)
- Table 5.15: Documents for Protecting Intellectual Property Rights
- Table 5.16: Specific Opportunities for Automated Instrumentation and
Reagent Systems in Mass Spectroscopy for Clinical Laboratory Testing
- Table 5.17: Strategies and POA for Marketing Clinical Laboratory
Diagnostic Products
- Table 7.1: Effect of Regulation on Molecular Diagnostics Clinical
Laboratory Market Technology Platforms, 2007-2015
- Table 7.2: Companies Utilizing New, Cutting-Edge Technologies to Develop,
Validate and Market Mass Spectroscopy Tests for Clinical Use
- Table 7.3: Impediments to Incorporating Promising Mass Spectroscopy Tests
into Clinical Practice
- Table 7.4: Alliances Showing the Greatest Synergy in Bringing Mass
Spectroscopy?s Tests to Market
|
